Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis

NCT ID: NCT02549001

Last Updated: 2018-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

953 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-20

Study Completion Date

2018-09-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether P-3058 nail solution is a safe and effective treatment for onychomycosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Onychomycosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

P-3058 10%

P-3058 10%

Group Type EXPERIMENTAL

P-3058 10%

Intervention Type DRUG

vehicle of P-3058 10%

vehicle of P-3058 10%

Group Type PLACEBO_COMPARATOR

vehicle of P-3058 10%

Intervention Type DRUG

amorolfine 5%

Loceryl®

Group Type ACTIVE_COMPARATOR

amorolfine 5%

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

P-3058 10%

Intervention Type DRUG

vehicle of P-3058 10%

Intervention Type DRUG

amorolfine 5%

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Loceryl®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Patients aged 12 years and older of any race.
* Males or females.
* Patients with onychomycosis involving ≥ 20% to ≤ 50% of target big toenail.
* Patients with a positive KOH examination and culture positive for dermatophyte

Exclusion Criteria

* Presence of "yellow spikes" on the target nail.
* Presence of dermatophytoma on the target nail.
* Presence of nail thickness exceeding 2 mm.
* Patients with proximal subungual involvement
* Patients with severe plantar or moccasin tinea pedis
* Patients with nail abnormalities due to other conditions
* Patients with life expectancy less than 2 years.
* Chemotherapy, immunosuppressive therapy in the 12 weeks prior to Screening visit (V1).
* Systemic corticosteroids, antimetabolites and immune-stimulants therapy in the 4 weeks prior to Screening visit (V1).
* HIV infection or any other immunodeficiency.
* Alcohol or substance abuse.
* Patients with history of allergic reactions to terbinafine or its excipients.
* Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Polichem S.A.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maurizio Caserini, MD

Role: STUDY_DIRECTOR

Polichem S.A.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Polichem Investigative Site

Multiple Locations, , Belgium

Site Status

Polichem Investigative Site

Multiple Locations, , Bulgaria

Site Status

Polichem Investigative Site

Multiple Locations, , Czechia

Site Status

Polichem Investigative Site

Multiple Locations, , Germany

Site Status

Polichem Investigative Site

Multiple Locations, , Greece

Site Status

Polichem Investigative Site

Multiple Locations, , Hungary

Site Status

Polichem Investigative Site

Various Cities in Iceland, , Iceland

Site Status

Polichem Investigative Site

Multiple Locations, , Latvia

Site Status

Polichem Investigative Site

Multiple Locations, , Lithuania

Site Status

Polichem Investigative Site

Multiple Locations, , Poland

Site Status

Polichem Investigative Site

Multiple Locations, , Russia

Site Status

Polichem Investigative Site

Multiple Locations, , Slovakia

Site Status

Polichem Investigative Site

Multiple Locations, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Bulgaria Czechia Germany Greece Hungary Iceland Latvia Lithuania Poland Russia Slovakia Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015-000561-31

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

PM1331

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.